Activation of LXRα improves cardiac remodeling induced by pulmonary artery hypertension in rats

Yibo Gong1, Yifeng Yang1, Qin Wu1, Ge Gao2, Yin Liu3, Yaoyao Xiong1, Can Huang1 & Sijie Wu1

Inflammatory factors regulated by NF-κB play a significant role in PAH and myocardial hypertrophy. LXR activation may inhibit myocardial hypertrophy via suppressing inflammatory pathways; it is unknown whether LXR is also involved in PAH-induced myocardial hypertrophy or remodeling. To further explore the protective effect of LXR in PAH-induced cardiac hypertrophy and remodeling, a PAH model was developed, and T0901317, an agonist of LXR, was used to examine the effect of LXR activation. PAH rats demonstrated obvious cardiac hypertrophy and remodeling in the right ventricle, but significant improvement of cardiac hypertrophy and remodeling was observed in PAH rats treated with T0901317. Through RT-PCR, Western blot and ELISA examination, NF-κB, IL-6, TNF-α, and iNOS were found to be significantly reduced in PAH rats treated with T0901317 compared to PAH rats treated with DMSO. Apoptosis was also significantly reduced in PAH rats treated with T0901317. Thus, LXR activation may inhibit PAH-induced cardiac hypertrophy and remodeling by inhibiting NF-κB-mediated inflammatory pathways.

Pulmonary artery hypertension (PAH) often coexists with congenital heart disease, and persistent PAH may lead to ventricular remodeling, right ventricle (RV) enlargement, and right heart failure1, 2. However, PAH-induced cardiac hypertrophy and remodeling is largely unstudied. Previous studies have demonstrated that PAH-induced RV enlargement leads to increases in cardiac oxygen consumption and decreases in perfusion, which subsequently accelerates RV remodeling and enlargement. Neuro-hormonal regulation abnormalities, reactive oxygen species (ROS) and reactive nitrogen species (RNS) imbalances, and inflammation may contribute to the disease pathology3, 5. Among these conditions, angiotensin II (ATII), endothelin-1 (ET-1), and neuro-hormones promote ROS formation, whereas endogenous nitric oxide (NO) and hemochrome are major resources for RNS formation. Tumor Necrosis Factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) are increased in both cardiocytes and the serum of patients with cardiac hypertrophy or failure6, 7. Reduced cardiac function in PAH-induced RV hypertrophy may also result from post-apoptotic fibrosis and increases in intercellular fibrin. It has also been recently shown that inhibition of NF-κB may counteract PAH-induced RV hypertrophy8.

Liver X Receptors (LXR), a member of the nuclear receptor super-family, was discovered by Willy et al. in a liver cDNA database in 1995. Two LXR isoforms, LXRα (NR1H3) and LXRβ (NR1H2), have been identified in mammals and share a high degree of amino acid similarity9. Initially, LXRs were considered important regulators of lipid metabolism. In recent years, the role of LXRs in cholesterol metabolism, glycometabolism, bile acid excretion, fatty acid metabolism, immunoregulation, and inflammation has been noted. Recent studies indicate that LXRs regulate the renin-angiotensin-aldosterone system (RAAS)10–14. LXRβ is stably expressed in all tissue types, whereas LXRα is mainly expressed in the liver, intestine, and brain. Recently, LXRα was also found to be expressed in the cardiovascular system and may play an important role in this system. Cardiac LXRs may be activated by myocardial infarction15, 16, chronic pressure overload17, 18, myocarditis19, and diabetes20, 21. Accumulating evidence implicates intracardiac LXR signaling in the protection against cardiac pathologies involving myocardio-cyte hypertrophy and loss, fibrosis, and metabolism dysfunction17, 18, 22. The molecular basis for the protective

1Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, China. 2Faculty of Laboratory Medicine, Xiangya Medical College, Central South University, Changsha, China. 3Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China. Correspondence and requests for materials should be addressed to S.W. (email: wusijie0605@sina.com)
actions of LXR\(\alpha\) on pathological hypertrophic growth has been elucidated\(^{18,23}\). LXR\(\alpha\) activation inhibits the NF-\(\kappa\)B signaling pathway, thus further inhibiting downstream cytokines and expression of target genes such as IL-6, inducible nitric oxide synthase (iNOS), Cyclooxygenase-2 (COX-2), and matrix metalloprotein-9 (MMP-9)\(^{24-26}\). Our previous research also showed that LXR\(\alpha\) activation may inhibit myocardial hypertrophy induced by lipopolysaccharide (LPS) or Ang II via suppression of the NF-\(\kappa\)B pathway in H9C2 cells\(^{18}\).

However, it is unknown whether LXR\(\alpha\) activation may also improve PAH-induced myocardial hypertrophy or remodeling in vivo. No relevant research has been published on this topic to date. In the present study, we examined the effect of LXR activation on myocardial remodeling in a rat PAH model and investigated its possible mechanism.

**Results**

**Monocrotatine (MCT) significantly induces PAH and myocardial remodeling in rats.** The data were collected on the 28th day after MCT administration, however, respiration frequency increase was observed since the third week in rats with PAH (Group P) relative to control group (Group C). When samples from lung tissues were assessed, lung tissues in Group C exhibited a pink color with good flexibility compared to the sporadic petechiae and decreased flexibility observed in Group P. Megascopic cardiac enlargement was also observed. Hematoxylin-eosin (HE) staining confirmed our suspicions of inflammatory cell invasion, increasing intercellular substance, cell hypertrophy, and apoptosis in the lungs and RV (Fig. 1A–D). Variations were noted in the

![Figure 1. MCT-induced pulmonary artery hypertension and cardiac hypertrophy in SD rats. After administration of MCT (Group P) and saline (Group C) for 28 days, HE staining was performed in the pulmonary artery (A,B) and right cardiac ventricle (C,D) (magnification 400X). The heart/weight ratio (E) (n = 6, *<0.05) and atrial natriuretic factor (ANF) RT-PCR analysis (F) (n = 6, *<0.05) revealed a significantly hypertrophied right ventricle in Group P.](image)
Invasive Hemodynamic Analysis on 28 days

| Parameters | Group C         | Group P         |
|------------|-----------------|-----------------|
| SAP (mmHg) | 135.7 ± 14.15   | 136.0 ± 13.36   |
| MAP (mmHg) | 117.1 ± 13.80   | 116.6 ± 11.26   |
| SPAP (mmHg)| 21.88 ± 4.299   | 44.57 ± 10.16*  |
| MPAP (mmHg)| 17.59 ± 2.866*  | 37.80 ± 8.762*  |
| MPAP/MAP   | 0.1497 ± 0.010* | 0.3210 ± 0.049* |
| HR (bmp)   | 26.26 ± 4.495   | 27.33 ± 6.132   |
| HR (bpm)   | 368.8 ± 32.97   | 372.8 ± 36.58   |

Table 1. Invasive hemodynamic analysis of rats in the PAH and control groups. n = 6, *Compare with Group C, p < 0.05.

Echocardiography Data on 28 days

| Parameters | Group C         | Group P         |
|------------|-----------------|-----------------|
| RV (mm)    | 4.386 ± 0.1491  | 6.184 ± 0.3632* |
| RA (mm)    | 4.512 ± 0.2468* | 6.433 ± 0.6390* |
| LV (mm)    | 4.355 ± 0.5716  | 4.802 ± 0.8888  |
| LA (mm)    | 3.539 ± 0.3327  | 3.301 ± 0.4191  |
| PA/AO      | 1.057 ± 0.09298 | 1.281 ± 0.1684* |

Table 2. Echocardiography examination results of rats in the PAH and control groups. n = 6, *Compare with Group C, p < 0.05.

Echocardiography Data on 35 days

| Parameters | Group CD         | Group CT         | Group PD         | Group PT         |
|------------|------------------|------------------|------------------|------------------|
| RV (mm)    | 4.64 ± 0.41      | 4.71 ± 0.25      | 6.82 ± 0.36*     | 6.59 ± 0.54*     |
| RA (mm)    | 4.77 ± 0.35      | 4.78 ± 0.26      | 7.09 ± 0.49*     | 6.78 ± 0.52*     |
| LV (mm)    | 4.73 ± 0.38      | 4.72 ± 0.32      | 4.82 ± 0.34      | 5.39 ± 1.1       |
| LA (mm)    | 3.83 ± 0.35      | 3.50 ± 0.30      | 3.70 ± 0.46      | 3.53 ± 0.50      |
| PA/AO      | 1.027 ± 0.063    | 1.008 ± 0.048    | 1.451 ± 0.134*   | 1.339 ± 0.096*   |

Table 3. Echocardiography examination results of rats in the PAH and control groups with or without LXR activation. n = 6, *Compare with Group CD, p < 0.05.

morphology and heart weight. The ratio of heart weight to body weight (2.983 ± 0.3499 vs. 2.057 ± 0.1548 in Group P and Group C, respectively, Fig. 1E, p < 0.05) was increased in Group P, indicating that cardiac hypotrophy in PAH rats is induced by MCT.

Invasive hemodynamic monitoring (IHM) is considered the gold standard for analysis and directly showed the degree of PAH on day 28 (Table 1). The systolic pulmonary artery pressure (SPAP) (44.57 ± 10.16 mmHg vs. 21.88 ± 4.299 mmHg, p < 0.05), mean pulmonary artery pressure (MPAP) (37.80 ± 8.762 mmHg vs. 17.59 ± 2.866 mmHg, p < 0.05), and mean pulmonary artery pressure/mean arterial pressure (MPAP/MAP) (0.3210 ± 0.049 vs. 0.1497 ± 0.010, p < 0.05) were increased almost 2-fold compared to the normal condition. Blood pressure (BP) and cardiac output (CO) exhibited no differences between the two groups. Ultrasonic cardiogram (UCG) analysis indicated that right heart system expansion occurred in Group P (6.184 ± 0.3632 mm vs. 4.386 ± 0.1491 mm in the RV and 6.433 ± 0.6390 mm vs. 4.512 ± 0.2468 mm in the right atrium (RA), Table 2, p < 0.05). An increase in another important PAH index in clinical practice, aorta/pulmonary artery (AO/PA), was also detected through UCG analysis (1.281 ± 0.1684 vs. 1.057 ± 0.09298, Table 2, p < 0.05). Real-time PCR (RT-PCR) was applied to analyze atrial natriuretic factor (ANF) mRNA levels on day 28 in the two groups (Fig. 1F). ANF was significantly increased in the cardiomyocytes of PAH rats.

In summary, PAH was induced in rats 28 days after MCT administration. Obvious cardiac hypertrophy and remodeling was observed in the right ventricle, with remarkable elevation of ANF expression.

Agitation of LXRα inhibits cardiac remodeling in PAH rats. After treatment of T0901317 or DMSO for 7 days, the four groups (PT, PD, CT, and CD) underwent morphological analysis. No significant differences were noted between the PT and PD groups regarding the heart/weight ratio or echocardiography after statistical analysis (Table 3). Differences were noted in further studies. IHM analysis indicated that the PT group exhibited reduced SPAP (41.21 ± 7.323 vs. 50.47 ± 7.220, p < 0.05), MPAP (32.97 ± 5.765 vs. 40.92 ± 5.33, p < 0.05) and MPAP/MAP (0.290 ± 0.035 vs. 0.34 ± 0.023, p < 0.05) (Table 4). HE staining revealed that cardiocytes in both the CD and CT groups were arranged as stripes with relatively large intercellular spaces, which is consistent with typical RV histological characteristics. However, cardiocytes in the PT group exhibited hypertrophy and were
slightly mal-arranged with occasional inflammatory cell infiltration, whereas the PD group exhibited the most hypertrophic cardiocytes with obvious apoptosis and massive inflammatory cell infiltration (Fig. 2). TUNEL staining revealed apoptotic cells in the RV of all PAH rats, and no apoptosis was observed in the control group without PAH. After T0901317 administration, apoptosis was significantly decreased compared to that in the PD group (7.4 ± 3.2 vs. 13.4 ± 5.0, p < 0.05) (Fig. 3), suggesting that LXR impeded the development of PAH and myocardial remodeling. Therefore, compared to PD group, pulmonary pressure in PT group was significantly decreased after T0901317 administration for 1 week, and the cardiac hypertrophy and apoptosis was improved as well. LXRα negatively regulates NF-κB, TNF-α, IL-6, and iNOS during myocardial remodeling in the PAH rat model. RT-PCR revealed increased expression of LXRα mRNA 7 days after T0901317 treatment in the CT and PT groups (Fig. 4). In addition, cardiac ANF expression was significantly increased in the PAH group compared to the control group and was significantly reduced in the PT group compared to the PD group. TNF-α, IL-6, and iNOS expression exhibited a similar change, as the mRNA expression in the PT group was significantly reduced compared to that in the PD group. Western blotting revealed the same trend in protein expression (Fig. 5). T0901317 administration significantly enhanced cardiac LXRα expression. PAH induced increased expression of inflammatory proteins such as NF-κB, IL-6, TNF-α, and iNOS, in cardiocytes. However, the expression of these proteins in cardiocytes was significantly reduced in the PT group compared to that in the PD group. An ELISA revealed a 4-fold increase in LXR in the PT and CT groups (Fig. 6). NF-κB exhibited a repressed trend with increased LXR expression. An ELISA revealed a significant reduction in NF-κB protein activation.

Table 4. Invasive hemodynamic analysis of rats in the PAH and control groups with or without LXR activation. n = 6, *Compare with Group CD, p < 0.05, Δ Compare with Group PD, p < 0.05.
in the PT group compared to that in the PD group. NF-κB controls the expression of most inflammatory and apoptosis factors. The down-regulation of NF-κB activity leads to a comprehensive reduction in TNF-α, IL-6 and iNOS following reduced mRNA expression.

Therefore, our study showed T0901317 administration activated LXR expression on myocardiocytes. It also inhibited ANF expression, as well as NF-κb, IL-6, TNF-a, iNOS expression.

Discussion

PAH is one of the most common causes of cardiac hypertrophy, remodeling, and heart failure, as increased pulmonary pressure leads to post-load increases, ventricular enlargement, and subsequent increases in oxygen consumption. These effects promote cardiocyte fibrosis, cardiac remodeling, and failure. The role of inflammatory signal pathways in cardiocyte hypertrophy and apoptosis has been emphasized in recent studies; however, its role in PAH-induced cardiocyte hypertrophy and remodeling remains elusive. Our previous research showed that LXR activation may inhibit the NF-κB signaling pathway in cardiocytes.

T0901317, an LXR agonist, activates the expression of both LXRα and LXRβ. LXRβ is stably expressed in multiple tissues, and LXRα is more specifically expressed in the liver, intestine, and heart. Our previous study demonstrated that both LXRα and LXRβ activation may inhibit the NF-κB signaling pathway in cardiocytes. However, LXRα may be more responsive and plays an even broader and more active role in regulating stresses exerted onto the heart. Thus, we examined only LXRα activation in this study.

In our study, at 28 days after MCT treatment, rats exhibited obvious PAH, right heart system expansion, and hypertrophy. These phenomena can be explained by activated inflammation and apoptosis systems and indicate the initiation of myocardial remodeling.

After 7 days of T0901317 administration, the pulmonary pressure in rats mildly decreased, and both the RV size and heart weight ratios exhibited slight decreases on UCG findings. However, the differences were not significant compared to the control group. This result may be affected by the T0901313 administration time. Although macroscopic changes in UCG and heart weight results did not reach statistical significance, a histological examination revealed that LXR activation significantly ameliorated PAH-induced cardiac hypertrophy, mal-arrangement, and fibrosis. Thus, we believe that LXR may to some extent inhibit PAH-induced cardiac hypertrophy. As one of the molecular markers of cardiac hypertrophy, ANF was significantly reduced in T0901317-treated PAH rats, confirming the protective effect of LXR activation. In addition, LXR activation also ameliorated cardiac apoptosis in the RV, which may contribute to its influence on cardiac remodeling.

Inflammation and apoptosis factors, such as iNOS, COX-2, IL-6, IL-1, and MMP-9, were induced by LPS and reduced by LXR. In this study, we measured NF-κB, TNF-α, IL-6, and iNOS expression levels in right ventricular tissues and noticed a significant increase in these classic inflammation and apoptosis factors. The
activation of NF-κB affects myocardial remodeling. Active NF-κB is transferred into the cell nucleus through IκB degradation29, and expression of genes that influence the production level of downstream inflammation and apoptosis factors is up-regulated. T0901317 suppressed NF-κB activity in the heart in PAH rats, suggesting that LXR inhibits cardiac hypertrophy and inflammation via the NF-κB signaling pathway. Our experiment showed that NF-κB and downstream IL-6 and TNF-α were significantly down-regulated. However, cardiac apoptosis and iNOS expression were reduced. Thus, LXR activation may inhibit cardiac fibrosis and remodeling by inhibiting the apoptotic pathway. Further experiments are warranted to confirm this finding.

As indicated in recent literature, LXR may inhibit toll-like receptor-4 (TLR-4) signaling in macrophages30. However, significant TLR-4 expression was not observed in this study and in our previous in vitro study. Thus, we assume that the TLR-4 pathway may not be involved in LXR-mediated inflammatory pathways. In addition, although AT1 is inhibited by LXR activation in smooth muscle31, we did not observe any significant difference in AT1 expression in PAH cardiocytes. Similar results were noted in our previous in vitro experiment. However, these findings await further confirmation.

Recent literature revealed that ROS might function as key mediators of mechanotransduction during both physiological adaptation to mechanical load and maladaptive remodeling of the heart32. LXR has also been shown to regulate cell survival through inhibition of ROS production and oxidative stress33,34, as well as prevent apoptosis induced by hyperglycemia35 and diabetes36. Our study also examined ROS expression change after LXR activation, but no stable results were obtained (data not shown). As sampling variation should be considered,
further research is warranted to confirm whether ROS signaling pathway is involved in LXR mediated improvement of right ventricular remodeling.

In summary, PAH may lead to RV hypertrophy and remodeling. The NF-κB-mediated inflammatory pathway may be a mechanism of inducing inflammatory and apoptotic cytokine expression, leading to subsequent cardiac hypertrophy and increased apoptosis and cardiac fibrosis. LXR activation may inhibit NF-κB and its downstream inflammatory cytokines, such as IL-1, TNF-α, and iNOS, which could improve PAH-induced cardiac hypertrophy and remodeling.

Methods
Animals and animal treatments. One hundred healthy SD rats were randomly divided into two groups (the control group (Group C) and PAH group (Group P), 50/group). Then, 60 mg/kg MCT was administered by
intraperitoneal injection to rats in Group P. Group C rats were administered the same dose of NS. After 28 days, 80 rats (40 randomly selected from each group) were separated into 4 groups. Group C was divided into the CD group, in which rats were treated with NS + DMSO, CT: rats treated with NS + T0901317, PD: rats treated with MCT + DMSO, PT, rats treated with MCT + T0901317). (n = 6, ∆: vs CD/PD P < 0.05, *vs CD P < 0.05, #vs PD P < 0.05).

**UCG detection.** UCGs were used to describe morphological changes at 28 and 35 days. Rats were narcotized by 10% chloral hydrate at a dose of 3 mg/kg. Data from the RV and the RA were collected from a four-chamber view, and data from the left ventricle (LV), left atrium (LA), and aorta (AO) were obtained from the long axis. Pulmonary artery (PA) data were derived from the horizontal shaft axis, and CO was obtained using the m-echo mode.

**Invasive hemodynamic monitoring.** As the gold standard of PAH, IHM was used to estimate the level of PAH at 28 and 35 days. SD rats underwent basic anesthesia and were supported using a ventilator. While sustaining sufentanil and vecuronium support, we opened the chest and pericardium and directly detected the PA.
pressure with a PE10 catheter imbedded into the PA through the right ventricular outflow tract (RVOT). BP and central venous pressure (CVP) were monitored at the arteria femoralis and jugular vein, respectively. All data were managed using PowerLab™.

**Gene expression analysis.** The TRIZOL reagent from Invitrogen was used to isolate total RNA. RT-PCR was performed using the Prime Script RT reagent kit with gDNA Eraser (Takara, Japan). Quantitative real-time PCR (qRT-PCR) was performed using the All-in-one™ TM qPCR Mix kit (Gene Copenien, USA). All primers for RT-PCR were synthesized at Sangon (Shanghai, China). RT-PCR results from each gene/primer pair were normalized to the results of β-actin and compared across conditions. The primer sequences used for qPCR amplification were as follows: LXRα: forward- AGG GCT GCA AGG GAT TCT TC, reverse- CCT CGA TCG CAG AAG TCT TC; IL-6: forward-ACA GTG CAT CAT CGC TGT TC, reverse-CCG GAG AGG AGA CTT CAC AG; TNF-α: forward-ACT CCC AGA AAA GCA AGC AA, reverse- CGA GCA GGA ATG AGA AGA GG; ANF: forward-CAC CTT GGA GTT CAC CCA GT, reverse-ACC ACT CTT ACT TGG GAT GC; iNOS: forward-CAC CTT GGA GTT CAC CCA GT, reverse-ACC ACT CTT ACT TGG GAT GC; β-actin: forward-CAT CCT CCG TCT GGA CCT GG, reverse-TAA TGT CAC GCA GTA TTT CC.

**Western blot analysis.** Nuclear and cytosolic proteins were extracted from RV tissue samples using a nuclear protein extraction kit (Pierce). Protein samples were subjected to SDS-PAGE and Western blotting using the Bio-Rad Image Lab program. Antibodies were obtained from commercial sources. LXRα, NF-κB p65, IL-6, TNF-α, and iNOS were obtained from Abcam, Inc. GAPDH was obtained from Xianzhi Biotechnology, China.

**Paraffin sections and HE staining.** After gradient dehydration at room temperature, myocardial tissues were embedded in paraffin and cooled in a 20 °C refrigerator for 1 hour. Tissue sections were cut at 5 microns, bathed in 45 °C water, and dried for preservation. After the sections were dried, hematoxylin was used for nuclei staining, and eosin was used to stain the cytoplasm after dewaxing and hydration. In the last step, the sections were sealed with neutral gum for observation.

**TUNEL staining.** All slides were incubated in dUTP labeled with 50 μl TdT and 450 μl fluorescein. The reaction was performed for 1 hour in the dark. For the negative control, only dUTP and 50 μl fluorescein were added. For the positive control, dUTP in combination with a 50 μl TdT and 450 μl fluorescein mixture was added after DNase treatment. After PBS washing, the converter-POD was reacted for 30 min at 37 °C. Finally, DAB staining was performed, and hematoxylin was used to stain the nucleus.

**Statistical analysis.** A t-test was used to analyze the UCG, invasive hemodynamic analysis, myocardial weight, RT-PCR, and Western blot data. One-way ANOVA was used to compare data among the four groups. A value of p < 0.05 was considered significant. All graphs were processed with GraphPad Prism 5.

**References.**

1. Vlahakes, G. J., Turley, K. & Hoffman, J. I. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. *Circulation*. 63, 87–95 (1981).

2. Zornoff, L. A. et al. SAVE Investigators. right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. *J Am Coll Cardiol.* 39, 1450–1455 (2002).

3. Humblet, M., Sitbon, O. & Simonneau, G. Treatment of pulmonary arterial hypertension. *N Engl J Med* 351, 1425–1436 (2004).

4. Silverman, K. J., Hutchins, G. M. & Bulkley, B. H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. *Circulation*. 58, 1204–1211 (1978).

5. Follansbee, W. P. et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). *J Rheumatol.* 17, 656–662 (1990).

6. Krohnbach, G. A. et al. Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. *J Magn Reson Imaging* 25, 1283–1287 (2007).

7. Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. *Circ Res*. 91, 988–998 (2002).

8. Kumar, S. et al. Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline. *Am J Physiol Heart Circ Physiol*. 302(8), H1655–66 (2012).

9. Willy, P. J. et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev.* 9(9), 1033–45 (1995).

10. Pent, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. *Cell*. 93(5), 693–704 (1998).

11. Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. *J Clin Invest* 116(3), 607–14 (2006).

12. Lo Sasso, G. et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. *Cell Metab.* 12(2), 187–93 (2010).

13. Korach-André, M., Archer, A., Barros, R. P., Parini, P. & Gustafsson, J. Å. Both liver X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. *Proc Natl Acad Sci USA*. 108(1), 403–8 (2011).

14. Steffensen, K. R. et al. Genome-wide expression profiling: a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. *J Mol. Endocrinol.* 33, 609–622 (2004).

15. He, Q. et al. Activations of liver-x-receptor alpha but not liver-x-receptor beta protects against myocardial ischemia/reperfusion injury. *Circ Heart Fail*. 7(6), 1032–1041 (2014).

16. Lei, P. et al. Activations of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury. *Basic Res Cardiol*. 108(1), 323 (2013).

17. Cannon, M. V. et al. The liver X receptor agonist AZ767 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. *Eur J Heart Fail*. 17(3), 273–282 (2015).

18. Wu, S. et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. *Cardiovasc Res.* 84(1), 119–26 (2009).

19. Papageorgiou, A. P. et al. Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. *Cardiovasc Res.* 107(1), 78–88 (2015).

20. Cheng, Y., Liu, G., Pan, Q., Guo, S. & Yang, X. Elevated expression of liver X receptor alpha (LXRalpha) in myocardium of streptozotocin-induced diabetic rats. *Inflammation*. 34(6), 698–706 (2011).
21. He, Q. et al. Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice. *Cardiovasc Diabetol.* **13**, 149 (2014).
22. Kuipers, I. et al. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. *Eur J Heart Fail* **12**(10), 1042–1050 (2010).
23. Cannon, M. V. et al. Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. *EMBO Mol Med.* **7**(9), 1229–1243 (2015).
24. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. *Nat Med.* **9**(2), 213–9 (2003).
25. Castrillo, A., Joseph, S. B., Marathe, C., Mangelsdorf, D. J. & Tontonoz, P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. *J Biol Chem* **278**(12), 10443–9 (2003).
26. Naiki, Y. et al. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. *J Immunol.* **181**(10), 7176–85 (2008).
27. Repa, J. J. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. *Science.* **289**, 1524–1529 (2000).
28. Apfel, R. et al. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. *Mol Cell Biol.* **14**, 7025–7035 (1994).
29. Thompson, J. E., Phillips, R. J., Erdjument-Bromage, H., Tempst, P. & Ghosh, S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. *Cell.* **80**(4), 573–82 (1995).
30. Fontaine, C. et al. Liver X receptor activation potentiates the lipopolysaccharide response in macrophages. *Circ Res.* **101**, 40–49 (2007).
31. Imayama, I. et al. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. *Hypertension.* **51**, 1631–1636 (2008).
32. Kitajima, N. et al. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. *Sci Rep.* **6**, 37001 (2016).
33. Gong, H. et al. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. *J Biol Chem.* **284**(44), 30113–30121 (2009).
34. Spillmann, F. et al. LXR agonism improves TNF-alpha-induced endothelial dysfunction in the absence of its cholesterol-modulating effects. *Atherosclerosis.* **232**(1), 1–9 (2014).
35. Cheng, Y. et al. Synthetic liver X receptor agonist T0901317 attenuates high glucose-induced oxidative stress, mitochondrial damage and apoptosis in cardiomyocytes. *Acta Histochem.* **116**(1), 214–221 (2014).
36. Rosenberg, H. C. & Rabinovitch, M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. *Am J Physiol Heart Circ Physiol.* **255**(6 Pt 2), H1484–91 (1988).
37. Escolá-Gil, J. C. et al. Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport in vivo. *Transl Res.* **161**(2), 110–7 (2013).
38. Solan, P. D. et al. Liver X receptor alpha activation with the synthetic ligand T0901317 reduces lung injury and inflammation after hemorrhage and resuscitation via inhibition of the nuclear factor kappa B pathway. *Shock.* **35**(4), 367–74 (2011).

Acknowledgements

This work was supported by a grant from the National Natural Science Foundation of China (81300084).

Author Contributions

S. Wu, Y. Gong, and Y. Yang participated in the design of this study, Y. Gong and G. Gao, Y. Xiong developed the animal model and performed molecular biological experiments. Q. Wu and C. Huang performed ultrasound cardiogram and histological examinations, S. Wu, Y. Gong and Y. Liu performed statistical analysis, S. Wu, Y. Gong and Y. Liu drafted the manuscript, Y. Yang revised the final manuscript, and all authors reviewed the manuscript.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017